Akoya to Report Third Quarter 2022 Financial Results on November 7th, 2022
11. Oktober 2022 08:05 ET
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the...
Akoya to Participate at Four Upcoming Investor Conferences
31. August 2022 08:05 ET
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in four upcoming...
Akoya Reports Second Quarter 2022 Operating Results and Raises Full Year 2022 Revenue Guidance
08. August 2022 16:05 ET
|
Akoya Biosciences, Inc.
Q2 2022 revenue $17.9 million, 37% y/y growthRaising FY 2022 revenue guidance range to $71-74 million MARLBOROUGH, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA)...
Akoya to Participate at Two Upcoming Investor Conferences
27. Juli 2022 08:05 ET
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in two upcoming...
Akoya to Report Second Quarter 2022 Financial Results on August 8th, 2022
12. Juli 2022 08:05 ET
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the...
Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic
28. Juni 2022 08:05 ET
|
Akoya Biosciences, Inc.
The OncoSignature® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced Phase 2 targeted...
Akoya Biosciences to Highlight Novel Spatial Transcriptomics Capabilities on PhenoCycler-Fusion at AGBT 2022 Annual Meeting
01. Juni 2022 08:05 ET
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, will present for the first time, data generated using its proprietary RNA...
Akoya Reports First Quarter 2022 Operating Results and Raises Full Year 2022 Revenue Guidance
05. Mai 2022 16:05 ET
|
Akoya Biosciences, Inc.
Q1 2022 revenue $16.9 million, 38% growth over prior year periodRaising FY 2022 revenue guidance range to $70-73 million MARLBOROUGH, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences,...
Akoya to Participate at Three Upcoming Investor Conferences
03. Mai 2022 08:05 ET
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in three upcoming...
Akoya Biosciences Announces Ehab A. El-Gabry, MD, as Chief Medical Officer
19. April 2022 08:05 ET
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced the appointment of Dr. Ehab A. El-Gabry as the company’s...